RESEARCH ARTICLE

REVISED Patient treatment pathways of multidrug-resistant tuberculosis cases in coastal South India: Road to a drug resistant tuberculosis center [version 5; peer review: 2 approved, 1 approved with reservations]

Priya Rath¹, Kalpita Shringarpure², Bhaskaran Unnikrishnan¹, Abhinav Pandey³, Abhirami Nair³

¹Department of Community Medicine, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, Karnataka, India

²Department of Preventive and Social Medicine, Medical College Baroda, Baroda, Gujarat, India

³Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, Karnataka, India

V5 First published: 16 Apr 2019, 8:498
<https://doi.org/10.12688/f1000research.17743.1>
 Second version: 13 May 2020, 8:498
<https://doi.org/10.12688/f1000research.17743.2>
 Third version: 27 May 2020, 8:498
<https://doi.org/10.12688/f1000research.17743.3>
 Fourth version: 22 Jul 2020, 8:498
<https://doi.org/10.12688/f1000research.17743.4>
 Latest published: 08 Jul 2021, 8:498
<https://doi.org/10.12688/f1000research.17743.5>

Abstract

Background: Delays in initiating multidrug-resistant tuberculosis (MDR TB) treatment adds risk to individual patients and the community due to disease progression, and on-going transmission. The Government of India offers free TB diagnosis and treatment, however many presumptive MDR TB patients wander within the Indian healthcare system and delay accessing the programme. To improve access to care, it is imperative to understand the treatment pathways taken by MDR TB patients. We aimed to describe the diagnostic and treatment pathway taken by presumptive MDR TB patients registered under Programmatic Management of Drug-resistant TB Program.

Methods: We conducted a cross-sectional study amongst patients registered during August 2016 – April 2017 at one District Drug Resistance Tuberculosis centre of Dakshina Kannada district in Karnataka, India. A semi-structured questionnaire was used to collect the number, type (private and public sector), and dates of healthcare facilities (HCFs) visits prior to the initiation of MDR TB treatment. Delays in pathway were measured in days and summarised as median and interquartile range (IQR), from the date of onset of illness until

Open Peer Review

Approval Status

	1	2	3
version 5			
(revision)			
08 Jul 2021	view		view
version 4			
(revision)			
22 Jul 2020			view
version 3			
(revision)			
27 May 2020	view	view	
version 2			
(revision)			
13 May 2020	view		
version 1			
16 Apr 2019	view	view	

1. Sharath Burugina Nagaraja , Employees State Insurance Corporation Medical College and Post Graduate Institute of Medical

the initiation of MDR TB treatment.

Results: We found that patients preferred private HCFs; however, due to lack of treatment and unaffordability they shifted to public HCFs. Median delay to register under the program was more in private HCFs (180 days) in comparison with public HCFs (120 days). We also found that the detection rates were much higher in public HCFs (80%).

Conclusion: The present study found that there was substantial patient delay and total delay in diagnosis and treatment of MDR TB patients. Private HCF was first point of contact for most of the patients; however those visited public HCF diagnosed earlier as compared to others. The government should involve private HCFs to provide standard diagnostics and treatment to the patients seeking a private facility.

Keywords

Diagnostic delay, Treatment delay, Patient delay, Health care system delay Programmatic management of Drug resistant TB, detection rate, Private health care facility, Public health care facility.

This article is included in the **Pathogens** gateway.

This article is included in the **Manipal Academy of Higher Education** gateway.

This article is included in the **Antimicrobial Resistance** collection.

Sciences and Research, Bengaluru, India

2. **Douglas Fraser Wares**, KNCV Tuberculosis Foundation, The Hague, The Netherlands

3. **Derrick Kimuli** , Uganda Bureau of Statistics, Kampala, Uganda

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Priya Rath (priya.rathi@manipal.edu)

Author roles: **Rathi P:** Conceptualization, Data Curation, Formal Analysis, Methodology, Project Administration, Resources, Software, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; **Shringarpure K:** Conceptualization, Formal Analysis, Methodology, Project Administration, Validation, Writing – Review & Editing; **Unnikrishnan B:** Methodology, Project Administration, Resources, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; **Pandey A:** Data Curation, Methodology, Software, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Nair A:** Data Curation, Formal Analysis, Methodology, Writing – Original Draft Preparation

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2021 Rath P *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Rath P, Shringarpure K, Unnikrishnan B *et al.* **Patient treatment pathways of multidrug-resistant tuberculosis cases in coastal South India: Road to a drug resistant tuberculosis center [version 5; peer review: 2 approved, 1 approved with reservations]** F1000Research 2021, 8:498 <https://doi.org/10.12688/f1000research.17743.5>

First published: 16 Apr 2019, 8:498 <https://doi.org/10.12688/f1000research.17743.1>

REVISED Amendments from Version 4

We have further elaborated on why a patient would have chosen private HCF as the first point of contact after developing symptoms suggestive of MDRTB in discussion paragraph two. We also have added a line on a mixed-method approach towards reducing the delay in the diagnosis and treatment of MDRTB wherein the private sector can be provided with incentives and funded treatment from the government to manage MDRTB cases at their HCF.

Any further responses from the reviewers can be found at the end of the article

Introduction

Multidrug-resistant tuberculosis (MDR TB), is defined as tuberculosis (TB) bacilli resistant to at least two first-line drugs — rifampicin and isoniazid. According to the Global TB Report 2019 published by the World Health Organization (WHO), India ranks first globally in the burden of TB and MDR TB attributing 27% and 24% of global burden respectively^{1,2}. Nearly 3% of new TB cases and 12% of previously treated patients in India are MDR TB^{2,3}.

To reduce transmission of MDR TB, the Government of India developed and implemented a national policy for the programmatic management of drug-resistant TB (PMDT) in 2007 under the Revised National Tuberculosis Control Programme (RNTCP), now renamed National Tuberculosis Elimination Programme (NTEP)⁴. The strategies and objectives of PMDT complement the National Strategic Plan for TB Elimination (2017–2025), and include treatment of MDR TB, enhancing laboratory systems for faster diagnosis, and offering social protection and supportive systems to ensure uninterrupted treatment with shorter, less toxic regimens^{4–6}.

Delays in MDR TB diagnosis and appropriate treatment initiation not only impacts individual patients, through advance disease progression, additional costs, and poor quality of life; but also in the community through increased risk of ongoing transmission to other individuals^{7,8}. The time taken to seek care, type of health care facility being sought and reasons for shifting from one health care facility to other are important factors for understanding delays in diagnosis, treatment initiation, and poor outcomes. Describing health seeking behaviours and pathways taken by persons presumed to be MDR TB case is a vital step in developing and implementing interventions that bridge the gap between timely diagnosis and treatment, and policies that improve the overall health system.

In India, approximately 20% of the patients in need of MDR TB treatment actually receive it, and among those who do receive and start treatment, less than half (48%) complete it successfully^{2,3}. These poor outcomes are largely due to lost to follow-up and premature deaths. In 2017, the proportion of deaths during MDR TB treatment in India was higher than the global average (21% vs. 14%)³.

Therefore, in this study we aimed to determine the health-seeking pathway of presumptive MDR TB patients prior to treatment at the PMDT centre. We also assessed the median time taken, and reasons for shifting from one health care facility (HCF) to another.

Methods

Study setting

The Dakshina Kannada (DK) district in Karnataka provinces of India includes 79 primary health centers (PHCs), five secondary referral hospitals (Taluk hospitals), one tertiary referral hospital (Wenlock Government hospital) and over 500 private practitioners. Mangalore is a second major city and is headquarters of DK, with a population of 600,000. This city is one of the major center for healthcare, with an inflow of patients not only from Mangalore but also from adjacent states of Kerala and Tamil Nadu.

We conducted a cross-sectional study of all patients registered during August 2016 – April 2017 at one District Drug Resistance Tuberculosis Centre (DDR-TBC) of DK district which also caters to two neighbouring districts of Chikmagalur and Udupi in Karnataka, India. It has ten inpatient beds, facilities for diagnosis, pre-treatment evaluation and treatment of DRTB, monitoring complications associated with second-line anti-tuberculosis treatment. After inpatient care to initiate treatment (approximately two weeks), the patient is released for continuation of care at Peripheral Health Institute (PHI) on an outpatient basis, with the help of identified treatment supporter throughout the community.

After obtaining Institutional Ethics Committee (IEC) approval from Kasturba Medical College Mangalore (IEC KMC MLR 11-16/328) and permission from DDR-TBC, all patients registered under DDR-TBC were asked to enrol in the study. A line list was taken from DDR-TBC on daily basis, and the patients present in DDR-TBC were approached by the Principal Investigator (PI). The purpose of the study was explained to the patients in their vernacular language and written informed consent was obtained from patients. Those who were illiterate, informed consent process was conducted in front of literate impartial witness⁹. PI collected data using a questionnaire to interview the patients.

Data collection

Face to face interviews were guided by a semi-structured questionnaire, which had been developed based on a literature review and the content was validated by experts in epidemiology (CDC Atlanta), a PMDT medical officer, and a layperson (local ground staff member working in the tertiary care hospital). Following this, the tool was field tested in two patients for ease of administration, who were not added in analysis. The interview enquired about the various healthcare facilities (HCFs) visited by the patient from the time they experienced TB symptoms, designated as a presumptive MDR patient (designated as a presumptive MDR patient which by definition

refers to the following patients: TB patients found positive on any follow-up sputum smear examination during treatment with first line drugs including treatment failures; - TB patients who are contacts of DR TB; - previously treated TB patients; - new TB patients with HIV co-infection⁴), until they registered for treatment at the PMDT centre. We noted the time interval and reason for shifting from one facility to another. All information was penned down on the questionnaire at the time of the interview without any audio or video recording. We also validated the starting point with the reports and patient file from the DDR-TBC to look for HIV coinfection, previous lab reports, history of contact, previous treatment history, if available.

Data analysis

Data collected was entered and analyzed using Statistical Package for Social Science (SPSS) version 11.5. Kolmogorov-Smirnov test was done to find the normality of data. Results were expressed in median and inter-quartile range (IQR). Chi-square test was performed to find out the association between type of HCF visited by patients and reasons for shifting from one HCF to the other. The patient treatment pathway has been used to express health seeking behavior of the patients and was created using Adobe Illustrator trial version. (Adobe Creative Cloud- Illustrator. Available from: <http://adobe.ly/28QoDIL>) The pathway was created using vector images with the visits being represented with different colors and different kinds of lines used for the diagnostic status of the patient. The meanings of both the lines as well the colors have been explained in the legends accompanying the pathways. Moreover, the number of patients shifting between HCF has been represented using the numbers accompanying the respective lines.

Operational definitions. Multidrug resistant TB (MDR-TB):

Patients with sputum-smear positive pulmonary TB, and at least one *M. tuberculosis* isolate with demonstrated resistance to at least isoniazid and rifampicin. Not all the health facilities involved in the study have the same diagnostic capacity. Under PMDT programme, DDR- TBC are developed, which complies with Standard Diagnostic and Treatment guidelines. Whereas other private establishments either refer the patient or send the samples to designated microscopic centres.

Presumptive MDR-TB patients: A presumptive MDR patient which by definition refers to the following patients: TB patients found positive on any follow-up sputum smear examination during treatment with first line drugs including treatment failures; - TB patients who are contacts of DR TB; - previously treated TB patients; - new TB patients with HIV co-infection¹⁰. This definition was used by the investigators to initiate the point of inquiry. It was irrespective of the definition used either by the government and private sector.

Pathway: The various type of HCF visited by a presumptive MDR patient before registering for PMDT treatment in a chronological sequence. The various HCF were merged into two broad types: private and public health care sectors. Public HCFs include Primary Health Centers (PHCs) and Public

Referral Hospitals (PRHs), including secondary and tertiary referral centers. Private HCF include secondary and tertiary referral center participating in Revised National Tuberculosis Control Program, non-participating allopathic clinics and practitioners (registered and unregistered) and Ayurveda Yoga Unani Sidda Homeopathy (AYUSH) practitioners¹¹. We have only considered those patients who were registered at DDR- TB Center and enquired regarding the health care facilities they visited prior to DDR-TB Center and their sequence to what happened there with respect to diagnosis, treatment and referral. For the patients in the government sector, registration is done under National Tuberculosis Elimination Programme (NTEP). For patients who are initiated with treatment in the private sector, are notified to the government using a the web enabled patient management system for TB control called as Nikshay. Cases which are notified is kept confidential and can be accessed only by appropriate government officials at state and national level⁵.

Time delays in the health care pathways¹²: The total delay is the time interval from the onset of illness until the initiation of anti MDR-TB drugs. It is the sum of two-time intervals: 1) diagnostic delay (time interval between the onset of symptoms and labelling of the patient as a MDR-TB patient); 2) treatment delay (time interval between MDR-TB diagnosis and initiation of anti MDR-TB drugs).

The total delay is also the sum of patient delay (time interval between onset of symptoms and presentation to first health care provider) and healthcare system delay (time interval between the date of health-seeking at a health care provider and the initiation of anti MDR-TB treatment), since it can be attributed to these types of delay.

Reasons for shifting from one HCF to another: These were the option provided to the patients-

1. Treatment not available, the appropriate treatment for the symptoms was unavailable in that HCF;
2. Treatment not affordable, cost of treatment was beyond the paying capacity of patient and their family;
3. Referred, patient was asked to visit another HCF for review/consultation or appropriate treatment;
4. Not satisfied, symptoms did not alleviate or the patient perceived that the services being provided were inadequate. Also, along with this, they were also asked of any other reasons.

Results

During the study period, a total of 55 patients were initiated on treatment at the DDR-TBC; however only 40 patients consented to participate in the study. Since the direction of inquiry was retrospective and the unit of inquiry was the patient or close relative, for the 15 patients who did not consent for the study, since they did not consent for study, we do not have access to information on their sociodemographic characteristics such as age, gender etc. However, with respect to current

diagnosis of TB and treatment regimen, they were same as both were done at DDR TBC with standard protocol and SOP.

The mean age in our study was 40 years (SD: 13.9). There were 28(70%) male patients and 12 (30%) female patients. In total, 35(87.5%) patients were educated till primary level, while only 5(12.5%) of patients were illiterate. A total of 26 (65%) of the study participants belonged to rural areas while only 14(45%) patients lived in an urban area.

Details of first visit and shift from one HCF to other HCF

Out of 40 patients interviewed, 15(37.5%) went to a public HCF and 25(62.5%) went to a private HCF as their first

clinical encounter (Figure 1 and Figure 2). In total, 23 (57.5%) were diagnosed with MDR TB during this encounter.

Amongst the 15 patients who went to the public HCF at the first encounter, 12 (80%) were diagnosed with MDR TB and were referred directly to the DDR-TBC., whilst the remaining three patients required additional visits before MDR diagnosis (two went to public HCF and one went to private HCF).

Amongst the 25 patients who went to the private sector at the first clinical encounter, 11 (44%) were microbiologically diagnosed with MDR TB, and were referred directly to the DDR-TBC. The remaining 14(66%) required addition visits

Figure 1. Patient diagnostic and treatment pathway.

Figure 2. Median time delay in treatment pathway of MDR Patients.

before MDR TB diagnosis (nine (36%) went to public HCF and five (20%) went to private HCF).

Details of second visit and shift from one HCF to other HCF

All 40 patients underwent a second visit: 18(45%) went to DDR-TBC, 15(37.5%) opted for public HCF, while seven (17.5%) went to private HCF. Out of the 17 undiagnosed patients, 14 (82.3%) were diagnosed in second visit with MDR TB.

Out of the 15 who went to public HCF for second visit, four were already diagnosed (two from public HCF and two from private HCF) and 11(73.3%) were undiagnosed. Of the 11 undiagnosed, ten (91%) were diagnosed on this visit and were

referred to the DDR-TBC. One undiagnosed patient went to another public sector. Out of four previously diagnosed patients, two were referred to DDR-TBC and two again shifted to another public sector HCF. Hence a total of 12(80%) patients out of 15 shifted to DDR-TBC and three visited other public HCF.

Seven patients went to private HCF for a second visit. Out of these seven, one was previously diagnosed in other private institution and six were undiagnosed (five came from private HCF and one from public HCF). In this visit, of the six patients who were undiagnosed, four were diagnosed. Five patients (one previously diagnosed and four newly diagnosed) visited DDR -TBC from a private HCF. Two still remained

undiagnosed. One went to the DDR-TBC. The other undiagnosed patient visited another private sector HCF.

Overall, 18 patients (12(66.6%) from public HCF and six(33.3%) from private HCF) visited DDR-TBC in their third visit.

Details of third and fourth visit and third shift from one HCF to other HCF

Of the 40 patients, 22 (55%) patients underwent a third visit to HCF. Among them, 18(82%) came to DDR-TBC, three went to public HCF while one went to the private sector. Out of the three who went to public HCF, one was undiagnosed and two were previously diagnosed (first visit). The undiagnosed case was diagnosed and referred to the DDR-TBC. The two previously diagnosed patients also went to DDR-TBC in their fourth visit.

One undiagnosed patient from the private HCF was diagnosed and referred to DDR-TBC in the fourth visit.

Time delay in treatment pathway of MDR patients

The total median (IQR) patient delay was found to be 25 (10, 60) days. For patients contacting public HCF as their first point of health care contact, the median patient delay was 30 days, while for those contacting private HCF, it was found to be 20 days. The total median(IQR) delay inclusive of health care delay among all patient was 237 (109, 491) days. The total median (IQR) delay among those who first visited private HCF was 455 (149,505) days, and those who first went to public HCF was 165 (105,410) days.

In the first visit among the 23 patients who were diagnosed to have MDR TB, the median delay in reaching the DDR-TBC after contacting the first HCF was 120 (30, 240) days. Median (IQR) delay in a public health care facility was 105 (60, 382) days with the highest being 1825 days, while in a private health care facility the median delay was 180 (10, 240) days with the highest being 300 days.

Among the patients diagnosed in second visit, the median delay in reaching DDR-TBC was 210 (82,270) days from the day of first HCF contact. In public HCF, this delay was found to be 195 (82,247) days with the highest being 365 days while it was 255 (105, 341) days in private HCF with the highest being 365 days.

One patient who remained in the public sector was diagnosed at his third visit with a delay of 210 days. Similarly, a patient who remained in the private sector was diagnosed after a delay 120 days on his third visit.

Furthermore, median delay among female patients (30 days) was more than male patients (20 days). Also patients aged more than 45 years had longer median delay of 30 days as compared to those below 45 years.

The most common reason for shifting from first to second HCF was referral (both public and private) followed by non-affordability (only seen in private HCFs) and non-satisfaction (seen

more in private HCFs). Similarly, the reasons for shifting from second to third HCF were referral (mostly in public), non-satisfaction and non-affordability in private. In the third shift, only reason given was referral to DDR-TBC (Table 1).

Discussion

MDR TB is an emerging disease in India. The disease is difficult to treat and treatment outcomes are poor, making it a potential public health threat in the future. Our study sheds light on patients' treatment pathway and reasons for shifting between health care providers for diagnosis and treatment for MDR TB.

In our study, 63% of patients went to private health care facilities (HCF) as first point of health care contact, which was higher than the average 48% as seen in a systematic review from India^{13,14}. This pattern is also seen in other studies done in India and in other developing countries^{14–20}. The health seeking behavior of a patient depends on the knowledge about the disease and availability of healthcare services severity of symptoms and social support available, ease of accessibility, affordability, and simplicity of the healthcare services, especially in a communicable and stigmatized disease like TB²¹. Studies conducted in India showed that most people had poor awareness about TB-related symptoms, transmission, and the services offered by the then National TB control programme^{22,23}. Moreover, patients in India have reported treatment barriers, such as, long distance between the TB centers and their homes, lack of confidence in the efficacy of government supplied medication, and the lack of privacy during directly observed treatment sessions^{16,22,24}. In contrast, the private health sector is mostly easily accessible to patients, they have easy registration process and lesser waiting time, however, the expertise in diagnosing and managing MDRTB may not be same as NTEP programme. All these reasons suggest a preference for private HCF as their preferred health provider for TB diagnosis and treatment but subsequently moved to public HCF.

Private sector poses many hurdles in TB control with respect to suboptimal care, lack of standard operating procedures in

Table 1. Reasons for shifting from one HCF to other.

Reasons for shifting	Public, n (%)	Private, n (%)
<i>First to second visit</i>		
Treatment not available	1 (50)	1 (50)
Treatment not affordable	0 (0)	8 (100)
Referred	13 (54.2)	11 (45.8)
Not satisfied	1 (16.7)	5 (83.3)
<i>Second to third visit</i>		
Treatment not affordable	0 (0)	2 (100)
Referred	14 (82.4)	3 (17.6)
Not satisfied	1 (33.5)	2 (66.7)

diagnosis and treatment, lack of accountability as compared to public sector^{25–27}.

However, there was a delay on the part of patients to report to their first point of health care contact after appearance of symptoms. The median delay was found to be 25 days which is slightly more than two weeks of the cough criterion issued by NTEP for TB screening. While comparing with other studies, the delay varied across the country, some studies found this delay more as compared to others^{16,26–31}. This shows the diversity in patient delay across India. Also, the median delay was found to be more among female patients as compared to male patients. This has been shown in various studies done in India as well as in other developing countries^{12,18}. The median delay was found to be greater among those who had public HCF as their first point of contact which has also been seen in the study done by Nimbarte *et al.*²⁷. This could be due to their procrastinating the health care contact.

In our study, (23/40) 57.5% of the patients were diagnosed at their first point of contact, while (14/17) 82.3% them were diagnosed at their second point of contact. The results are similar to those seen in the study done by Ananthakrishnan *et al.*³⁰. Among the 55% of patients who made a second visit to a different HCF other than DDR-TBC, two thirds of the patients went to a public HCF. This is also seen in the study done by Charles *et al.*³². Also we found that in all the visits, the rate of diagnosis at public HCF was always more than that at private HCF. This could be due to improper tests done for detection or lack of technologies at private HCF³³.

The most common reason for shifting between HCF other than referrals was unaffordability followed by dissatisfaction. This is in contrast to the study done by Charles *et al.* where the major reason was found to be dissatisfaction with the available HCF followed by unaffordability³². In public HCF, the most common reason was referral which was in accordance to the PMDT guidelines.

Conclusion

The present study found that there was substantial patient delay and total delay in diagnosis and treatment of DR TB patients. Private HCF was first point of contact for most of the patients, however those who approached public HCF were diagnosed earlier as compared to others. The study projects

the need of a public-private collaboration in treating DR TB cases; in terms of linkages between public and private sector for diagnosis and treatment of drug resistance TB, orientation of private HCF towards standard diagnostic services under NTEP, and government funded treatment at low to no costs at private HCFs may be considered to curb the delay. This may be achieved by incentivizing treatment and providing standard diagnostic modalities to private sector under NTEP.

Limitations- This study was conducted among the 40 patients from one DDR-TBC of Karnataka therefore the findings can only be generalized to the population seeking health care from the same DDR-TBC. Second limitation would be the subject variability of the definition, however we have made full effort to validate the findings with medical reports of the patients from DDR-TBC to ensure the starting and end point of the pathway. Since the study was based on recall of the patients, there are chances of inherent recall bias.

Data availability

Underlying data

According to the IEC of Medical College Mangalore, we are not permitted to share data with any external agency for protection of data as it contains information which is personal and can be identified. However, if required by anyone, the data can be requested from the corresponding author after full justification of usage of the information. Conditions of access: researchers must use the data for similar research or sufficiently anonymize and give due credit to the authors of this study.

Extended data

Open Science Framework: Patient treatment pathways of multidrug-resistant tuberculosis cases in coastal South India: Road to a drug resistant tuberculosis centre: Structured questionnaire, <https://doi.org/10.17605/OSF.IO/TQNUE>³⁴

Data are available under the terms of the [Creative Commons Zero “No rights reserved” data waiver](#) (CC0 1.0 Public domain dedication).

Acknowledgments

We acknowledge Dr Patrick K Moonan, U.S. Centers of Disease Control and Prevention, Division of Global HIV and Tuberculosis, Atlanta USA for his valuable inputs and contributions in the study.

References

1. World Health Organization: **Global tuberculosis report 2019**. 2019. [Reference Source](#)
2. Ministry of Health and Family welfare: **National Anti-TB Drug Resistance Survey**. [Reference Source](#)
3. World Health Organization: **Global tuberculosis report 2018**. 2018. [Reference Source](#)
4. Ministry of Health and Family Welfare: **Guidelines on Programmatic Management of Drug-Resistant Tuberculosis in India**. 2017. [Reference Source](#)
5. Bhavan N: **National Strategic Plan for Tuberculosis Elimination 2017-2025**. Ministry of Health and Family welfare; 2017; 109. [Reference Source](#)
6. Falzon D, Jaramillo E, Schünemann HJ, *et al.*: **WHO guidelines for the**

- programmatic management of drug-resistant tuberculosis: 2011 update.** *Eur Respir J.* 2011; **38**(3): 516–528.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Zerbini E, Chirico MC, Salvadores B, *et al.*: **Delay in tuberculosis diagnosis and treatment in four provinces of Argentina.** *Int J Tuberc Lung Dis.* 2008; **12**(1): 63–68.
[PubMed Abstract](#)
 8. Shewade HD, Gupta V, Satyanarayana S, *et al.*: **Patient Characteristics, Health Seeking and Delays Among New Sputum Smear Positive TB Patients Identified Through Active Case Finding When Compared to Passive Case Finding in India.** *PLoS One.* 2019; **14**(3): e0213345.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 9. ICMR: **National Ethical Guidelines for Biomedical And Health Research involving Human Participants.** 2017.
[Reference Source](#)
 10. Ministry of Health and Family Welfare: **Guidelines on Programmatic Management of Drug-Resistant Tuberculosis in India.** 2017.
[Reference Source](#)
 11. Veesa KS, John KR, Moonan PK, *et al.*: **Diagnostic pathways and direct medical costs incurred by new adult pulmonary tuberculosis patients prior to anti-tuberculosis treatment - Tamil Nadu, India.** *PLoS One.* 2018; **13**(2): e0191591.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 12. Soliman SS: **Diagnostic and treatment delay in Tuberculosis.** Geneva: Metropole; 2006; 48.
[Reference Source](#)
 13. Rajeswari R, Chandrasekaran V, Suhadev M, *et al.*: **Factors Associated With Patient and Health System Delays in the Diagnosis of Tuberculosis in South India.** *Int J Tuberc Lung Dis.* 2002; **6**(9): 789–795.
[PubMed Abstract](#)
 14. Samal J: **Health Seeking Behaviour Among Tuberculosis Patients in India: A Systematic Review.** *J Clin Diagn Res.* 2016; **10**(10): LE01–LE06.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 15. World Health Organization: **Diagnostic and treatment delay in tuberculosis.** 2006. 2017.
[Reference Source](#)
 16. Goel K, Kondagunta N, Soans SJ: **Reasons for patient delays & health system delays for tuberculosis in south India.** *Indian J Community Health.* 2011; **23**(2): 87–9.
[Reference Source](#)
 17. Karanjekar VD, Gujarathi VV, Lokare PO: **Socio demographic factors associated with health seeking behavior of chest symptomatics in urban slums of Aurangabad City, India.** *Int J Appl Basic Med Res.* 2014.
[Reference Source](#)
 18. Kaur M, Sodhi S, Kaur P, *et al.*: **Gender differences in health care seeking behaviour of tuberculosis patients in Chandigarh.** *Indian J Tuberc.* 2013; **60**(4): 217–222.
[Reference Source](#)
 19. Bawankule S, Quazi SZ, Gaidhane A: **Delay in DOTS for new pulmonary tuberculosis patient from rural area of Wardha District, India.** *Online J Health Allied Sci.* 2010; **9**(1).
[Reference Source](#)
 20. Selvam JM, Wares F, Perumal M, *et al.*: **Health-seeking behaviour of new smear-positive TB patients under a DOTS programme in Tamil Nadu, India, 2003.** *Int J Tuberc Lung Dis.* 2007; **11**(2): 161–167.
[PubMed Abstract](#)
 21. Bonadonna LV, Saunders MJ, Zegarra R, *et al.*: **Why wait? The social determinants underlying tuberculosis diagnostic delay.** *PLoS One.* 2017; **12**(9): e0185018.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 22. Pinto LM, Udawadia ZF: **Private patient perceptions about a public programme; what do private Indian tuberculosis patients really feel about directly observed treatment?** *BMC Public Health.* 2010; **10**: 357.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 23. Sreeramareddy CT, Qin ZZ, Satyanarayana S, *et al.*: **Delays in diagnosis and treatment of pulmonary tuberculosis in India: a systematic review.** *Int J Tuberc Lung Dis.* 2014; **18**(3): 255–266.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 24. Jayachandran V: **A case study on tuberculosis treatment defaulters in Delhi: Weak health links of the community with the public sector, unsupported migrants and some misconceptions.** *Annals of Tropical Medicine and Public Health.* 2014; **7**(2): 124–129.
[Publisher Full Text](#)
 25. Arinaminpathy N, Batra D, Khaparde S, *et al.*: **The number of privately treated tuberculosis cases in India: an estimation from drug sales data.** *Lancet Infect Dis.* 2016; **16**(11): 1255–1260.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 26. Dhanvij P, Joshi R, Kalantri S: **Delay in diagnosis of tuberculosis in patients presenting to a tertiary care hospital in rural central India.** *J MGIMS.* 2009; **14**(ii): 56–63.
[Reference Source](#)
 27. Nimbarte S, Wagh V, Selokar D: **Health seeking behaviour among pulmonary tuberculosis patients in rural part of central India.** *Int J Biol Med Res.* 2011.
[Reference Source](#)
 28. Shamim H, Shalini S, Sneha K, *et al.*: **Health Care seeking Behavior of Cough Symptomatics (Pulmonary Tuberculosis Suspects) Attending Medicine Outpatient Department of a Tertiary Care Hospital of Jharkhand.** *IJIMS.* 2015; **2**(8): 42–49.
[Reference Source](#)
 29. Kulkarni P, Kulkarni A, Akarte S, *et al.*: **Treatment seeking behavior and related delays by pulmonary tuberculosis patients in E-ward of Mumbai Municipal Corporation, India.** *IJMEDPH.* 2013; **3**(4): 286.
[Publisher Full Text](#)
 30. Ananthakrishnan R, Jeyaraju AR, Palani G, *et al.*: **Care Seeking Behavior of the TB Patients who were Registered in an Urban Government Tuberculosis Control in Chennai, Tamilnadu, India.** *J Clin Diagn Res.* 2012; **6**(6): 990–3.
[Reference Source](#)
 31. Kapoor SK, Raman AV, Sachdeva KS, *et al.*: **How did the TB patients reach DOTS services in Delhi? A study of patient treatment seeking behavior.** *PLoS One.* 2012; **7**(8): e42458.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 32. Charles N, Thomas B, Watson B, *et al.*: **Care seeking behavior of chest symptomatics: a community based study done in South India after the implementation of the RNTCP.** *PLoS One.* 2010; **5**(9): e12379.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 33. Satyanarayana S, Subbaraman R, Shete P, *et al.*: **Quality of tuberculosis care in India: a systematic review.** *Int J Tuberc Lung Dis.* 2015; **19**(7): 751–763.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 34. Rathi P: **Patient Treatment Pathways of Multidrug-Resistant Tuberculosis Cases in Coastal South India: Road to a Drug Resistant Tuberculosis Center.** *OSF.* 2019.
<http://www.doi.org/10.17605/OSF.IO/TQNUF>

Open Peer Review

Current Peer Review Status:

Version 5

Reviewer Report 12 July 2021

<https://doi.org/10.5256/f1000research.58432.r89238>

© 2021 Kimuli D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Derrick Kimuli

Uganda Bureau of Statistics, Kampala, Uganda

Thank you for responding to my previous comments. Ensuring clarity so that the reader is able to understand the context of the article from the Author's point of view is important. Thanks, again.

Just one minor comment on Paragraph 3, " Private sector poses many hurdles in TB control with respect to suboptimal care, lack of standard operating procedures in diagnosis and treatment, lack of accountability as compared to public sector".

This just should be joined logically to either the previous or the proceeding paragraph.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Public Health Research

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 09 July 2021

<https://doi.org/10.5256/f1000research.58432.r89239>

© 2021 Burugina Nagaraja S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sharath Burugina Nagaraja

Department of Community Medicine, Employees State Insurance Corporation Medical College and Post Graduate Institute of Medical Sciences and Research, Bengaluru, Karnataka, India

No further comments to make.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Tuberculosis, HIV, Diabetes, COVID

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 4

Reviewer Report 10 May 2021

<https://doi.org/10.5256/f1000research.28235.r84550>

© 2021 Kimuli D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Derrick Kimuli

Uganda Bureau of Statistics, Kampala, Uganda

General comment:

- This is an informative paper. Understanding the points of delay is essential in developing approaches to improve the diagnosis and treatment of DR-TB. However, the paper could use a more in-depth approach to the discussion of the findings. I state some examples below but this could be considered a general comment.

Second last paragraph:

- The poor outcomes notice in India could also be a consequence of the findings of this study.

Discussion:

- Paragraph 2: You may need to elaborate more clearly as to why the first point of health contact was Private HCFs. Could this be attributed to the fact that they have a higher reach than Public HCFs? It is also possible that the Private HCFs are not able to handle MDR TB treatment or could it be that they can but it is very expensive? This doesn't come out well in the discussion yet it is part of the conclusion.

Conclusion:

- "provisions of standard diagnostic services and treatment at low to no costs" is hardly possible. You could make more precise and realistic recommendations based on your understanding of the context area.

Other comments:

- You could use some additional language editing.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

No

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Public health, TB

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 05 Jul 2021

Priya Rathi, Kasturba Medical College Hospital, Manipal, India

Reviewer's comment

Authors reply

Line/paragraph

The poor outcomes notice in India could also be a consequence of the findings of this study. Dear Reviewer- This paragraph is the justification of conducting this study based on existing evidence prior to the study, hence we have not added the finding of the study in the introduction paragraph.

Introduction- Second last paragraph

Discussion:

Paragraph 2: You may need to elaborate more clearly as to why the first point of health contact was Private HCFs. Could this be attributed to the fact that they have a higher reach than Public HCFs? It is also possible that the Private HCFs are not able to handle MDR TB treatment or could it be that they can but it is very expensive? This doesn't come out well in the discussion yet it is part of the conclusion.

Thank you for the suggestions, we have improvised in the justification and discussion on why the first point of contact would be the private HCFs incorporating the points suggested. Availability of the healthcare services, ease of access, and less complicated registration process in the private health care sector,
We also incorporated lack of the expertise and cost required to diagnose and manage MDRTB in the private sector as the reasons for shifting to the public sector on later visits.
Discussion – Paragraph 2

Conclusion:

"provisions of standard diagnostic services and treatment at low to no costs" are hardly possible. You could make more precise and realistic recommendations based on your understanding of the context area

Dear Reviewers, In India, standard diagnostic services and no-cost treatment have been provided to all MDRTB registered patients.

But they must bear the cost of management at private HCF, In conclusion, we are recommending a mixed approach wherein the private sector can provide the same treatment funded by the government.

Conclusion.

Competing Interests: Nil

Version 3

Reviewer Report 13 July 2020

<https://doi.org/10.5256/f1000research.26824.r63971>

© 2020 Wares D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Douglas Fraser Wares

KNCV Tuberculosis Foundation, The Hague, The Netherlands

Second review (12/07/20) of "Patient treatment pathways of multidrug-resistant tuberculosis cases in coastal South India: Road to a drug resistant tuberculosis center" paper for F1000Research

The authors have answered the vast majority of the comments raised in the earlier versions. However, there are a number of comments which could be addressed if possible prior to full approval. My major and minor comments follow, namely:

Major comments:

1. In the flowchart and text, the authors talk about "Presumptive MDR-TB patients". However, the patients enrolled in the study are diagnosed and registered MDR-TB cases. These are

not the same thing. How is “Presumptive MDR-TB patients” defined and is the same definition being used in both the private and public sector facilities in the study?

The above has been addressed by the authors in the revised version. However the second query of “whether similar levels of identification of “Presumptive MDR-TB patients” was being done in the different sector facilities?”, has not been answered. If it is possible, this could be added.

2. Time to diagnosis will be determined to a degree by what diagnostic capacity is available in the respective health facility. Hence if a facility has the capacity for rapid molecular diagnosis of TB and rifampicin resistance (RR-TB) e.g. if it has a GeneXpert machine on site, then diagnosis of RR-TB can be done within the day. If not and the patient or sample has to be sent to another facility which then does only culture and phenotypic drug susceptibility testing (DST) and not rapid molecular DST, there will be an inherent time difference between the patients seen at the initial health facility. So did all the health facilities involved in the study have the same access to diagnostic capacity?

Although the authors mention that the diagnostic capacity is not the same across the health facilities and sectors, no details are included. If it is possible to add details, then this should be done.

3. Even if the diagnostic capacity available to all health facilities involved in the study, where any RR-/MDR-TB cases diagnosed but not registered? If yes, were the proportions the same in the different sectors analysed?

Crucial segments of the author’s response to the above query should be added to the actual manuscript.

4. Were the 15 DR-TB patients who did not consent to participate in the study similar to the 40 patients who did participate in the study? Was there any difference in these 15 patients between those who initially visited a public sector facility versus those who visited a private facility initially?

Crucial segments of the author’s response to the above query should be added to the actual manuscript. A number of data should be available on these 15 patients (e.g. sex, age, etc) from the records and could be included in the manuscript.

Minor comments:

1. Introduction, 1st paragraph, 2nd sentence: Is the use of “.. incidence rate”... correct here?
2. Methods, study setting, 1st paragraph, 2nd sentence: “.. six lakhs..” should be amended to “600,000” for non-Indian readers understanding.
3. Methods, data collection, 3rd sentence, reference 10: Is this not the same reference as used for number 4?
4. Results, details of the first visit, and shift from one HCF to another HCF, 2nd paragraph, 1st sentence: Is it more correct to say that the patients were “referred” to the DDR-TBC rather than “transferred” as they had not yet started on treatment?

5. Results, Time delay in treatment pathway of MDR patients: I do not see mention of total delays here?
6. Results, Time delay in treatment pathway of MDR patients, 5th paragraph: Better to use "longer" rather than "more".
7. Results, Table 1: Why are a number of the lines repeated (i.e. Treatment not affordable/Not affordable; Referred; Not satisfied) as there is no explanation to why they appear twice?
8. Discussion, 4th paragraph, 2nd sentence: Is the median delay not "25 days"?
9. Discussion, 4th paragraph, 6th sentence: Is it meant to be stated as references "18, 12, 32".
10. Conclusions, 2nd sentence: Not sure that "diagnostic rate" is the correct term to be used here as it has not been calculated in the results section?
11. Limitations, 1st sentence: Amend to " ... the findings can *only* be generalized.."

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Partly

Are all the source data underlying the results available to ensure full reproducibility?

Partly

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Drug resistant TB, implementation of new and/or novel drug regimens

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 20 Jul 2020

Priya Rathi, Kasturba Medical College Hospital, Manipal, India

Reviewer's Name - Douglas Fraser Wares

In the flowchart and text, the authors talk about "Presumptive MDR-TB patients". However, the patients enrolled in the study are diagnosed and registered MDR-TB cases. These are not the same thing. How is "Presumptive MDR-TB patients" defined and is the same definition being used in both the private and public sector facilities in the study?

The above has been addressed by the authors in the revised version. However, the second query of "whether similar levels of identification of "Presumptive MDR-TB patients" was being done in the different sector facilities?", has not been answered. If it is possible, this could be added.

This study was a retrospective inquiry on the pathway taken to reach Drug Resistance TB Center, which is run by the Government.

The starting point of this inquiry was taken from the time these patients were presumptive DR case which by definition as per Programmatic Management of Drug Resistant Tuberculosis Guidelines is:

Presumptive MDR case is any of the following: and it refers to the following patients in order of their risk:

TB patients found positive on any follow-up sputum smear examination during treatment with first line drugs including treatment failures; - TB patients who are contacts of DR-TB; - previously treated TB patients; - new TB patients with HIV co-infection. The point of inquiry started from the time Patients fulfilled any of the above criteria. Since we have not interviewed any of the private HCF we cannot comment if they used the same criteria.

Method -Data collection, Operational definition.

Time to diagnosis will be determined to a degree by what diagnostic capacity is available in the respective health facility. Hence if a facility has the capacity for rapid molecular diagnosis of TB and rifampicin resistance (RR-TB) e.g. if it has a GeneXpert machine on site, then diagnosis of RR-TB can be done within the day. If not and the patient or sample has to be sent to another facility which then does only culture and phenotypic drug susceptibility testing (DST) and not rapid molecular DST, there will be an inherent time difference between the patients seen at the initial health facility. So did all the health facilities involved in the study have the same access to diagnostic capacity?

Although the authors mention that the diagnostic capacity is not the same across the health facilities and sectors, no details are included. If it is possible to add details, then this should be done.

Not all the health facilities involved in the study have the same diagnostic capacity. We have tried to highlight the same in our study; i.e. those patients who visited such health care facilities, which lacked standard diagnostic facilities were diagnosed late as compared to those who visited the government health care facility which has better diagnostic facility with Standard Operating Procedures (SOPs) and standard of care with respect to DR-TB. Under PMDT programme, DDR- TB centers are developed which complies with Standard

Diagnostic and Treatment guidelines. The private practitioners or other small healthcare establishments which are not designated microscopic centers either refer the patient or send the samples to DMCs for diagnosis.

The relevant text has been added in manuscript in the result section

Sdjhje

Even if the diagnostic capacity available to all health facilities involved in the study, where any RR-/MDR-TB cases diagnosed but not registered? If yes, were the proportions the same in the different sectors analysed?

Crucial segments of the author's response to the above query should be added to the actual manuscript.

We have only considered those patients who were registered at DDR- TB Center and enquired which health care facilities they visited prior to DDR-TB Center and their sequence to what happened there with respect to diagnosis and treatment and referral.

For the patients in the government sector, registration is done under the National TB Program. For patients who are initiated with treatment in the private sector, the private sector notifies this to the government. In this study, our objective was to find out the pathway and the source of information was the patient themselves and not the health care providers. Hence, we did not enquire on the notification of the cases if diagnosed at private sector. . For the patients in the government sector, registration is done under National Tuberculosis Elimination Programme (NTEP). For patients who are initiated with treatment in the private sector, are notified to the government using a the web enabled patient management system for TB control called as Nikshay. Cases which are notified is kept confidential and can be accessed only by appropriate government officials at state and national level

We have now added the relevant text in main manuscript

Method –Data collection, Operational definition

Were the 15 DR-TB patients who did not consent to participate in the study similar to the 40 patients who did participate in the study? Was there any difference in these 15 patients between those who initially visited a public sector facility versus those who visited a private facility initially?

Crucial segments of the author's response to the above query should be added to the actual manuscript. A number of data should be available on these 15 patients (e.g. sex, age, etc) from the records and could be included in the manuscript.

Since the direction of inquiry was retrospective and the unit of inquiry was the patient or close relative, in the 15 patients who did not consent for the study, we were unable to find their first point of contact to Health care facility.

However, with respect to current diagnosis of TB and treatment regimen, they were same as both were diagnosed at DRTB center with standard protocol and SOP.

Result paragraph 1

Introduction, 1st paragraph, 2nd sentence: Is the use of ". incidence rate" ... correct here?

Yes they developed TB in 2017 which was reported in the global report., however we have changed the sentence to avoid confusion

Introduction para 1

Methods, study setting, 1st paragraph, 2nd sentence: "... six lakhs." should be amended to "600,000" for non-Indian readers understanding.

Done

Methods, study setting, 1st paragraph, 2nd sentence:

Methods, data collection, 3rd sentence, reference 10: Is this not the same reference as used for number 4?

Yes, we Agree and we have now changed it to ref 4

Methods, data collection, 3rd sentence

Results, details of the first visit, and shift from one HCF to another HCF, 2nd paragraph, 1st sentence: Is it more correct to say that the patients were "referred" to the DDR-TBC rather than "transferred" as they had not yet started on treatment?

We have changed the word transferred to referred

Results, details of the first visit, and shift from one HCF to another HCF, 2nd paragraph, 1st sentence

Results, Time delay in treatment pathway of MDR patients: I do not see mention of total delays here? Added

We have now added total delays as well the following has been added to the manuscript
The total median(IQR) delay inclusive of health care delay among all patient was 237 (109, 491) days. The total median (IQR) delay among those who first visited private HCF was 455 (149,505) days, and those who first went to public HCF was 165 (105,410) days.

Result, time delay --- paragraph 1

Results, Time delay in treatment pathway of MDR patients, 5th paragraph: Better to use "longer" rather than "more".

We have used "longer" instead of "more".

Results, Time delay in treatment pathway of MDR patients, 5th paragraph

Results, Table 1: Why are a number of the lines repeated (i.e. Treatment not affordable/Not affordable; Referred; Not satisfied) as there is no explanation to why they appear twice?

The sub heading of the tables were missing, we have now included that.

Table 1

Discussion, 4th paragraph, 2nd sentence: Is the median delay not "25 days"

Yes, we changed it to 25 days now

Discussion, 4th paragraph, 2nd sentence

Discussion, 4th paragraph, 6th sentence: Is it meant to be stated as references "18, 12, 32".

We have now removed ref 32 for this sentence and have interchanged the sequence in citation

Conclusions, 2nd sentence: Not sure that “diagnostic rate” is the correct term to be used here as it has not been calculated in the results section?

We have now removed the word diagnostic rate from conclusion and have added the following statement “those who approached public HCF were diagnosed earlier as compared to others”

Conclusion, 2nd sentence

Limitations, 1st sentence: Amend to “ ... the findings can only be generalized..”

We have added the word “only”

Competing Interests: Nil

Reviewer Report 29 May 2020

<https://doi.org/10.5256/f1000research.26824.r63972>

© 2020 Burugina Nagaraja S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sharath Burugina Nagaraja

Department of Community Medicine, Employees State Insurance Corporation Medical College and Post Graduate Institute of Medical Sciences and Research, Bengaluru, Karnataka, India

The authors have addressed my earlier comments and I have no further comments.

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Partly

Are all the source data underlying the results available to ensure full reproducibility?

Partly

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Tuberculosis, HIV, Diabetes - Operational Research

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 29 May 2020

Priya Rathi, Kasturba Medical College Hospital, Manipal, India

We thank Dr Sharath B for helping us in improving the manuscript and final approval of the same.

Dr Priya Rathi with all Co-authors

Competing Interests: Nil

Version 2

Reviewer Report 20 May 2020

<https://doi.org/10.5256/f1000research.26326.r63372>

© 2020 Burugina Nagaraja S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sharath Burugina Nagaraja

Department of Community Medicine, Employees State Insurance Corporation Medical College and Post Graduate Institute of Medical Sciences and Research, Bengaluru, Karnataka, India

The majority of the comments are addressed. However, please find a few minor comments that need your attention:

1. In Study settings: first paragraph, consider using "catchment area" or any other word rather than "drainage". Please rephrase the statement.
2. In conclusion: I am skeptical about the words "diagnostic yield" - the study was not designed to measure the diagnostic yield. Please rephrase the sentence.

Thank you with regards,
Sharath BN

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Partly

Are all the source data underlying the results available to ensure full reproducibility?

Partly

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Tuberculosis, HIV, Diabetes - Operational Research

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 21 May 2020

Priya Rathi, Kasturba Medical College Hospital, Manipal, India

1. In Study settings: first paragraph, consider using "catchment area" or any other word rather than "drainage". Please rephrase the statement.

Authors reply - Word "drainage" has been replaced by "inflow" in study setting first paragraph.

2. In conclusion: I am skeptical about the words "diagnostic yield" - the study was not designed to measure the diagnostic yield. Please rephrase the sentence.

Authors reply - "Diagnostic yield" has been replaced by "diagnostic rate" in the conclusion.

Competing Interests: Nil

Version 1

Reviewer Report 06 February 2020

<https://doi.org/10.5256/f1000research.19401.r59044>

© 2020 Wares D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Douglas Fraser Wares

KNCV Tuberculosis Foundation, The Hague, The Netherlands

Review of "Patient treatment pathways of multidrug-resistant tuberculosis cases in coastal South India: Road to a drug resistant tuberculosis center" paper for F1000Research.

The authors have written about an important topic related to the treatment pathways of drug-resistant TB patients in India. The manuscript reads well, however I have a number of major comments which need to be addressed to ensure the scientific level of the manuscript is raised. My major and minor comments follow, namely:

Major comments:

1. In the flowchart and text, the authors talk about "Presumptive MDR-TB patients". However the patients enrolled in the study are diagnosed and registered MDR-TB cases. These are not the same thing. How is "Presumptive MDR-TB patients" defined and is the same definition being used in both the private and public sector facilities in the study? This needs to be stated by the authors and how the "Presumptive MDR-TB patients" are being identified in the facilities of the 2 sectors and whether similar levels of identification of "Presumptive MDR-TB patients" was being done in the different sector facilities?
2. Time to diagnosis will be determined to a degree by what diagnostic capacity is available in the respective health facility. Hence if a facility has the capacity for rapid molecular diagnosis of TB and rifampicin resistance (RR-TB) e.g. if it has a GeneXpert machine on site, then diagnosis of RR-TB can be done within the day. If not and the patient or sample has to be sent to another facility which then does only culture and phenotypic drug susceptibility testing (DST) and not rapid molecular DST, there will be an inherent time difference between the patients seen at the initial health facility. So did all the health facilities involved in the study have the same access to diagnostic capacity?
3. Even if the diagnostic capacity available to all health facilities involved in the study, where any RR-/MDR-TB cases diagnosed but not registered? If yes, were the proportions the same in the different sectors analysed?
4. Were the 15 DR-TB patients who did not consent to be participate in the study similar to the 40 patients who did participate in the study? Was there any difference in these 15 patients between those who initially visited a public sector facility versus those who visited a private facility initially?

Minor comments:

1. Reference 1 and related text could be updated as the WHO 2019 Global TB Report is available.
2. Introduction, 2nd paragraph. It should be stated that PMDT is part of the Revised National TB Control Programme (now renamed as the National TB Elimination Programme) and is not a separate programme as implied by the current text.
3. Introduction, 2nd paragraph. Reference 5 should be updated as it refers currently to a 2011 WHO document which has been updated since then.
4. Introduction, 3rd paragraph. Reference 6 is from a paper dealing with Argentina. Is there no relevant reference paper from India that could be used instead? Also does the current reference paper talk about DS-TB and/or DR-TB?
5. Methods, Study settings, 1st paragraph. The district name and hospital name where the PMDT centre is located should be given. As should the names of the 3 districts that the centre caters for.
6. Methods, Study settings, 1st paragraph. For non-Indian readers, the meaning of "... by Kayakalp." needs to be explained. Also the reference given is no. 6 which refers to a paper dealing with Argentina and hence seems incorrect.
7. Methods, Study settings, 1st paragraph. The authors mention "... DOTS-Plus centres" and only mention about initial in-patient care. DOTS-Plus is outdated terminology and initial in-patient care practice alone is outdated practice under RNTCP. The text should be amended so the reader understand what is current RNTCP terminology and practice. Especially as in Figure 1, the term of DR-TB Centre is used.
8. Methods, Study settings, 2nd paragraph. 12.5% of patients in the study were illiterate, hence how was "written consent" given?
9. Methods, Data collection, 1st paragraph. Is it correct then that there was no actual field testing of the questionnaire prior to the study being conducted? What training did the PI have on the questionnaire prior to conducting the patient interviews?
10. Methods, Operational definitions, reasons for shifting from one HCF to another, 1st paragraph. As pointed out by the previous reviewer, what is listed here are options or answers expected to be provided by the patients. Hence this part of the methods section needs revising.
11. Results, 1st paragraph. Need to be consistent in the use of both numbers and % in the last sentence.
12. Results, Details of first visit and shift from one HCF to other HCF, 2nd paragraph. Although 12 of the 15 who initially visited a public HCF were diagnosed with MDR, only 10 were immediately referred to the DR-TB centre. Why did the 2 other patients have to attend a HCF for a 2nd time before referral to the DR-TB Centre?

13. Discussion. As stated by the previous reviewer, the authors spend a lot of the discussion section comparing with other studies. Many of the times this is just in relation to confirming previous observations. Such text could be reduced (e.g. 2nd and 4th paragraphs).
14. Discussion, 2nd paragraph. Should ease of access to service be more prominent amongst important issues surrounding health seeking behavior of patients? Is this not a major reason why patients initially seek care in the private sector rather than the public sector?
15. Discussion, 3rd paragraph. DR-TB is now more of a “transmitted” disease rather than the “acquired resistance” as discussed in the first few sentences of the paragraph. This needs to be noted. Also the meaning of the sentence “Further, the private sector poses many hurdles in TB control.” is unclear?
16. Discussion, 5th paragraph. For clarity of reading, the authors should to include the actual numbers involved when they state “57.5%” (=23/40) and “82.3” (=14/17).
17. Discussion, 6th paragraph. Did the study by Charles *et al.* (ref 28) include DR-TB cases as well as DS-TB? If not, how relevant is the reference to the current study?
18. Limitations. The authors need to include a paragraph or two on “Limitations” of the study.
19. Conclusions. Some of the statements made are pretty sweeping with little data or evidence from the study to support them. For example the statements in the 1st paragraph made about female and the elderly – these are based on very small patients numbers and hence how valid and generalizable are they? In the 2nd paragraph, an alternative view is that there may be better awareness in the community of the disease and availability of services. Hence a higher proportion of those who actually have the disease present to the public sector facilities for their 1st visit. And surely better linkages between the HCFs of the two sectors needs to be established, in addition to the option of providing everything in all private HCFs?
20. Consistency of language. DOTS-Plus centers / DR-TB Centre / PMDT center are all used in the manuscript. Firstly I would suggest the authors use “centre” and “programme”, and also are consistent in the term they use for the centre where the DR-TB patients were registered.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Programmatic care and control of tuberculosis; drug-resistant tuberculosis

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 02 May 2020

Priya Rathi, Kasturba Medical College Hospital, Manipal, India

We have answered all query/comments point to point and have indicated its current location in modified manuscript.

In the flowchart and text, the authors talk about "Presumptive MDR-TB patients". However, the patients enrolled in the study are diagnosed and registered MDR-TB cases. These are not the same thing. How is "Presumptive MDR-TB patients" defined and is the same definition being used in both the private and public sector facilities in the study? This needs to be stated by the authors and how the "Presumptive MDR-TB patients" are being identified in the facilities of the 2 sectors and whether similar levels of identification of "Presumptive MDR-TB patients" was being done in the different sector facilities?

This study was a retrospective inquiry on pathway taken to reach Drug Resistance TB Center. The starting point of this inquiry was taken from the time these patients were presumptive DR case which by definition as per Programmatic Management of Drug Resistant Tuberculosis Guidelines is: Presumptive MDR case are Any of the following: It refers to the following patients in order of their risk: TB patients found positive on any follow-up sputum smear examination during treatment with first-line drugs including treatment failures; - TB patients who are contacts of DR-TB; - previously treated TB patients; - new TB patients with HIV co-infection. These definitions were used in the study.

Method –Data collection, Operational definition.

Time to diagnosis will be determined to a degree by what diagnostic capacity is available in the respective health facility. Hence if a facility has the capacity for rapid molecular diagnosis of TB and rifampicin resistance (RR-TB) e.g. if it has a GeneXpert machine on site, then diagnosis of RR-TB can be done within the day. If not and the patient or sample has to be sent to another facility which then does only culture and phenotypic drug susceptibility

testing (DST) and not rapid molecular DST, there will be an inherent time difference between the patients seen at the initial health facility. So did all the health facilities involved in the study have the same access to diagnostic capacity?

Not all the health facilities involved in the study have the same diagnostic capacity. This is what we are trying to bring out from our study, that those patients who visited such health care facility which lacked Standard Diagnostic facilities were diagnosed late as compare to those who visited Government Health facility which has better diagnostic facility with Standard Operating Procedures (SOPs) and standard of care with respect to DR-TB. Under PMDT programme, DDR- TB centers are developed which complies with Standard Diagnostic and Treatment guidelines.

Even if the diagnostic capacity available to all health facilities involved in the study, where any RR-/MDR-TB cases diagnosed but not registered? If yes, were the proportions the same in the different sectors analyzed?

We have only considered those patients who were registered at DDR- TB Center and enquired which health care facilities they visited prior to DRTB Center and their sequence to what happened there with respect to diagnosis and treatment and referral. For the patients in the Government Sector, registration is done under the National TB Program. For patients who are initiated with treatment in the private sector, the private sector notifies to the government. In this study, our objective was to find out the pathway and the source of information was the patient themselves and not the health care providers. Hence, we did not enquire on the notification of the cases if diagnosed at private sector.

Were the 15 DR-TB patients who did not consent to participate in the study similar to the 40 patients who did participate in the study? Was there any difference in these 15 patients between those who initially visited a public sector facility versus those who visited a private facility initially?

Since the direction of inquiry was retrospective and the unit of inquiry was the patient or close relative, in the 15 patients who did not consent for the study, we were unable to find their first point of contact to Health care facility. However, with respect to the current diagnosis of TB and treatment regimen, they were the same as both were done at DRTB center with standard protocol and SOP.

Reference 1 and related text could be updated as the WHO 2019 Global TB Report is available. We have changed the reference to the latest report.

Reference 1

Introduction, 2 paragraph. It should be stated that PMDT is part of the Revised National TB Control Programme (now renamed as the National TB Elimination Programme) and is not a separate programme as implied by the current text.

We have mentioned it now and have highlighted it as well.

Introduction, 2nd paragraph.

Introduction, 2 paragraph. Reference 5 should be updated as it refers currently to a 2011 WHO document which has been updated since then.

We have updated the same.

Introduction, 2nd paragraph
Reference 5.

Introduction, 3 paragraph. Reference 6 is from a paper dealing with Argentina. Is there no relevant reference paper from India that could be used instead? Also, does the current reference paper talk about DS-TB and/or DR-TB?

We have not taken any data from the Argentina study, we have just cited the conceptual knowledge of delay in diagnosis, hence the same reference can be used, the study included DS and Previously treated TB patients. We have also added one Indian study as well, however it covers only a few points as compared to Argentina study

Introduction, 3rd paragraph. Reference 6 and 7

Methods, Study settings, 1 paragraph. The district name and hospital name where the PMDT Centre is located should be given. As should the names of the 3 districts that the Centre caters for.

The DRTB center is situated in district hospital of Dakshina Kannada District, Karnataka State, India which also caters to two neighboring districts of Chikmagalur and Shimoga. This has been included now in the first paragraph.

Methods, Study settings, paragraph 2

Methods, Study settings, 1 paragraph. For non-Indian readers, the meaning of "... by Kayakalp." needs to be explained. Also, the reference given is no. 6 which refers to a paper dealing with Argentina and hence seems incorrect.

This has been removed and the above statement has been mentioned instead.

Methods, Study settings, 2nd paragraph

Methods, Study settings, 1 paragraph. The authors mention "... DOTS-Plus centers" and only mention about initial in-patient care. DOTS-Plus is outdated terminology and initial in-patient care practice alone is outdated practice under RNTCP. The text should be amended so the reader understands what is current RNTCP terminology and practice. Especially as in Figure 1, the term of DR-TB Centre is used.

We have changed the terms to District Drug resistance TB center (DDR-TBC) and Peripheral Health Institution (PHI) as per PMDT guidelines.

Methods, Study settings, paragraph 3

Study settings, 2nd paragraph. 12.5% of patients in the study were illiterate, hence how was "written consent" given

Those who were illiterate, the informed consent process was conducted in front of literate impartial witness as per ICMR ethics guidelines.(https://www.icmr.nic.in/sites/default/files/guidelines/ICMR_Ethical_Guidelines_2017.pdf)

Reference 8

Methods, Data collection, 1st paragraph. Is it correct then that there was no actual field testing of the questionnaire prior to the study being conducted? What training did the PI have on the questionnaire prior to conducting the patient interviews?

The tool was pilot tested in two patients. PI holds an MD degree in Community Medicine, where there is training in epidemiology and has conducted multiple projects in the past. The questionnaire was content to validate independently by two experts and discussed for feasibility along with the pilot testing.

Not applicable

Methods, Operational definitions, reasons for shifting from one HCF to another, 1st paragraph. As pointed out by the previous reviewer, what is listed here are options or answers expected to be provided by the patients. Hence this part of the methods section needs revising.

We have modified the section as Follows-These were the options provided to the patients-1. treatment not available, the appropriate treatment for the symptoms was unavailable in that HCF; 2. treatment not affordable, cost of treatment was beyond the paying capacity of the patient and its family; 3. referred, the patient was asked to visit another HCF for review/consultation or appropriate treatment; 4. not satisfied, symptoms did not alleviate or the patient perceived that the services being provided were inadequate. Also, along with this, they were also asked if any other reasons not included in the list.

Methods- Operational definition

Result-1st paragraph. Need to be consistent in the use of both numbers and % in the last sentence.

We have improvised the result with consistency.

Result-1st paragraph

Results, Details of first visit and shift from one HCF to other HCF, 2nd paragraph. Although 12 of the 15 who initially visited a public HCF were diagnosed with MDR, only 10 were immediately referred to the DR-TB center. Why did the 2 other patients have to attend a HCF for a 2nd time before referral to the DR-TB Centre?

These two patients were from the other districts, they were referred from PHC to District hospital of the concerned district and from there to the DDR-TBC.

Discussion. As stated by the previous reviewer, the authors spend a lot of the discussion section comparing with other studies. Many of the times this is just in relation to confirming previous observations. Such text could be reduced (e.g. 2nd and 4th paragraphs).

We have modified the discussion as suggested, we have removed the comparing figures and have only mentioned relevant texts, we have reduced 2nd and 4th paragraph
Discussion

Discussion, 2nd paragraph. Should ease of access to service be more prominent amongst important issues surrounding health seeking behavior of patients? Is this not a major reason why patients initially seek care in the private sector rather than the public sector?

Yes, we have incorporated the point in the discussion

Discussion Paragraph 2

Discussion, 3rd paragraph. DR-TB is now more of a "transmitted" disease rather than the "acquired resistance" as discussed in the first few sentences of the paragraph. This needs to be noted. Also the meaning of the sentence "Further, the private sector poses many hurdles in TB control." is unclear?

There are both kind of cases, acquired as well as transmitted, we have now included your point in our discussion, also we have explained how the private sector can hinder the outcome of DRTB

Discussion paragraph 2

Discussion, 5th paragraph. For clarity of reading, the authors should to include the actual numbers involved when they state "57.5%" (=23/40) and "82.3" (=14/17).

Changes have been incorporated

Discussion paragraph 4

Discussion, 6th paragraph. Did the study by Charles et al. (ref 28) include DR-TB cases as well as DS-TB? If not, how relevant is the reference to the current study?

We have removed this part of the discussion.

Not applicable

Limitations. The authors need to include a paragraph or two on "Limitations" of the study.

Thank you for the insight. We have incorporated the paragraph for limitation.

Limitation reads as:

This study was conducted among the 40 patients from one DDR-TBC of Karnataka therefore

the findings can be generalized to the population seeking health care from the same DDR-TBC. Second limitation would be the subject variability of the definition, however we have made full effort to validate the findings with medical reports of the patients from DDR-TBC to ensure the starting and end point of the pathway. Since the study was based on recall of the patients, there are chances of inherent recall bias.

Limitation

Conclusions. Some of the statements made are pretty sweeping with little data or evidence from the study to support them. For example, the statements in the 1st paragraph made about female and the elderly – these are based on very small patients numbers and hence how valid and generalizable are they? In the 2nd paragraph, an alternative view is that there may be better awareness in the community of the disease and availability of services. Hence a higher proportion of those who actually have the disease present to the public sector facilities for their 1st visit. And surely better linkages between the HCFs of the two sectors needs to be established, in addition to the option of providing everything in all private HCFs?

We have modified the conclusion based on your suggestion.

Conclusion read as-

The present study found that there was substantial patient delay and total delay in diagnosis and treatment of DR TB patients. The study projects the need of a public-private collaboration in treating DR TB cases; in terms of linkages between public and private sector for diagnosis and treatment of drug resistance TB, provisions of standard diagnostic services and treatment at low to no costs. This may be achieved by incentivizing treatment and providing standard diagnostic modalities to private sector under NTEP.

Conclusion

Consistency of language. DOTS-Plus centers / DR-TB Centre / PMDT center are all used in the manuscript. Firstly I would suggest the authors use “centre” and “programme”, and also are consistent in the term they use for the centre where the DR-TB patients were registered.

We have changed it to District drug resistance TB center (DDR-TBC), We have also clarified and changed center and programme.

All throughout the manuscript

Competing Interests: Nil

Reviewer Report 16 September 2019

<https://doi.org/10.5256/f1000research.19401.r52457>

© 2019 Burugina Nagaraja S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sharath Burugina Nagaraja

Department of Community Medicine, Employees State Insurance Corporation Medical College and Post Graduate Institute of Medical Sciences and Research, Bengaluru, Karnataka, India

I congratulate your efforts on working on treatment pathways of drug resistant TB patients. Overall, the manuscript reads well. However, I have few comments for your consideration which will help in betterment of the manuscript. The comments are mentioned separately below.

Comments:

1. The authors in the introduction state that “we aimed to determine the health- seeking pathway of presumptive MDR TB patients prior to treatment at the PMDT center”. The manuscript lacks clarity on identifying the presumptive MDR-TB patient under the programmatic settings. Probably, the authors should specifically say that the presumptive MDR-TB is based on laboratory diagnosis rather than a clinical presumption.
2. Study settings: The authors have to specify the name of the hospital, location of the PMDT centre with the names and population of the districts it is catering to. They should also briefly describe about the types/numbers of public and private health facilities in the districts.
3. The statement “the patient is released to outpatient care for continuation of care at Directly Observed Treatment (DOT-Plus) centers throughout the community” needs to be modified because under programmatic conditions the patients are referred for domiciliary care in the community.
4. The name of the institution which has accrued ethics approval needs to be mentioned.
5. Data collection: It is found that the details were collected from the time the patients experience TB symptoms. These details are not analysed and was beyond the scope of the study. For a patient, there is a thin line of difference from being a presumptive TB case and a presumptive DR-TB case. There could be a lot of subjective variability in remembering the things which have occurred in the past. It is better if the authors explain the measures taken to negate such variability during the process of interview and increased their accuracy of findings.
6. Data analysis: Please mention the reference for adobe illustrator trail version.
7. Time delays in health care pathways: I feel the definitions needs further clarity. The starting point for delay calculations is the point of onset of illness. We presume that the authors are taking into account that it is from the point when the patient has a laboratory diagnosis of DR-TB. The authors should explicitly mention in their definitions.
8. Reasons for shifting from one HCF to others: These are the options or answers expected from the patients. They have to be presented in the results as the findings of patients’ interviews. Hence, should be removed from the method section.
9. Results: For better understanding the authors have to describe their findings as numbers (percentages). The ‘p’ values mentioned in table 1 should be removed, it has no relevance.

10. Among the 25 patients who went to private sector, 11 were diagnosed as MDR TB. What type of diagnosis did the private sector facilities made? Clinical or laboratory diagnosis? It is also mentioned that the patients are transferred to PMDT centres. Under programmatic settings, the transfer happens from one RNTCP administrative unit to the other.
11. There is a scope for authors to present the findings of proportions of patients who underwent 1,2,3 and 4 HCF visits as a bar diagram/table stratified by public and private facilities.
12. Discussions: The authors should remain focused on the study context. There has been much comparison with other studies. This tends to lose the focus of the readers. The recommendations have to be relevant to the study findings.
13. Limitations: The authors can add a paragraph on limitations of the study (response rate, sample size, generalizability, definitions-subjective variability).
14. Conclusion: The conclusion should be specific and should be described in a paragraph.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Tuberculosis, HIV, Diabetes - Operational Research

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 02 May 2020

Priya Rathi, Kasturba Medical College Hospital, Manipal, India

I congratulate your efforts on working on treatment pathways of drug resistant TB patients. Overall, the manuscript reads well. However, I have few comments for your consideration which will help in the betterment of the manuscript. The comments are mentioned separately below.

We thank the reviewer for the kind words of appreciation and recognising the work behind the manuscript. We have answered all query/comments point to point and have indicated its current location in the modified manuscript.

The authors in the introduction state that “we aimed to determine the health- seeking pathway of presumptive MDR TB patients prior to treatment at the PMDT centre”. The manuscript lacks clarity on identifying the presumptive MDR-TB patient under the programmatic settings. Probably, the authors should specifically say that the presumptive MDR-TB is based on laboratory diagnosis rather than a clinical presumption.

We have now included the exact definition of a presumptive diagnosis of DRTB based on PMDT guidelines

Methods data collection paragraph 2 and operational definition

Study settings: The authors have to specify the name of the hospital, location of the PMDT centre with the names and population of the districts it is catering to. They should also briefly describe about the types/numbers of public and private health facilities in the districts.

We have now specified the facility name, location and other details as suggested by the reviewer

Methods. Study setting paragraph 1

The statement “the patient is released to outpatient care for continuation of care at Directly Observed Treatment (DOT-Plus) centers throughout the community” needs to be modified because under programmatic conditions the patients are referred for domiciliary care in the community.

We have now changed this based on the PMDT guidelines

Methods. Study setting paragraph 2

The name of the institution which has accrued ethics approval needs to be mentioned.

Name of the IEC has been added

Methods. Study setting paragraph 3

Data collection: It is found that the details were collected from the time the patients experience TB symptoms. These details are not analysed and was beyond the scope of the study. For a patient, there is a thin line of difference from being a presumptive TB case and a presumptive DR-TB case.

There could be a lot of subjective variability in remembering the things which have occurred in the past. It is better if the authors explain the measures taken to negate such variability during the process of interview and increased their accuracy of findings.

We have mentioned the measures taken for alleviating subjectivity as follows

We validated the starting point with the reports and patient file from the DDR-TBC to look for HIV co infection, previous lab reports, history of contact, previous treatment history, if available.

Data collection

Data analysis: Please mention the reference for adobe illustrator trail version.

We have incorporated the reference and link

Data analysis

Time delays in health care pathways: I feel the definitions needs further clarity. The starting point for delay calculations is the point of onset of illness. We presume that the authors are taking into account that it is from the point when the patient has a laboratory diagnosis of DR-TB. The authors should explicitly mention in their definitions.

We have changed the definition to make it clearer to understand.

Operational Definitions

Reasons for shifting from one HCF to others: These are the options or answers expected from the patients. They have to be presented in the results as the findings of patients' interviews. Hence, should be removed from the method section.

These were the options given to the patients hence we have mentioned in both the sections

Results:

For better understanding, the authors have to describe their findings as numbers (percentages). The 'p' values mentioned in table 1 should be removed, it has no relevance.

We have included the numbers and also removed p-value from table 1

Among the 25 patients who went to private sector, 11 were diagnosed as MDR TB. What type of diagnosis did the private sector facilities made? Clinical or laboratory diagnosis? It is also mentioned that the patients are transferred to PMDT centres. Under programmatic settings, the transfer happens from one RNTCP administrative unit to the other.

There are private sectors with diagnostic facilities, hence the diagnosis refers to laboratory diagnosis. We meant, that the patient was referred to the public sector from the private sector

Details of first visit and shift from one HCF to other HCF

Paragraph 3

There is a scope for authors to present the findings of proportions of patients who underwent 1,2,3 and 4 HCF visits as a bar diagram/table stratified by public and private facilities.

Since our objective was to map the pathway, we have incorporated the different color lines for different number of visit (1,2,3,4)

This has been explained in the data analysis section as follows

The meanings of both the lines as well the colours have been explained in the legends accompanying the pathways. Moreover, the number of patients shifting between HCF has been represented using the numbers accompanying the respective lines.

Data-analysis

Figure 2 legends

Discussions: The authors should remain focused on the study context. There has been much comparison with other studies. This tends to lose the focus of the readers. The recommendations have to be relevant to the study findings.

We have now removed the comparing figures and have kept only relevant text
Discussion

Limitations: The authors can add a paragraph on limitations of the study (response rate, sample size, generalisability, definitions-subjective variability).

Thank you for your insight. We have incorporated the paragraph for limitation.

Limitation reads as

This study was conducted among the 40 patients from one DDR-TBC of Karnataka therefore the findings can be generalized to the population seeking health care from the same DDR-TBC. Second limitation would be the subject variability of the definition, however we have made full effort to validate the findings with medical reports of the patients from DDR-TBC to ensure the starting and end point of the pathway. Since the study was based on recall of the patients, there are chances of inherent recall bias.

Limitation

Conclusion: The conclusion should be specific and should be described in a paragraph.

We have made it specific and conveyed it in a single paragraph.

Conclusion read as-

The present study found that there was substantial patient delay and total delay in diagnosis and treatment of DR TB patients. The study projects the need of a public-private collaboration in treating DR TB cases; in terms of linkages between public and private sector for diagnosis and treatment of drug resistance TB, provisions of standard diagnostic services and treatment at low to no costs. This may be achieved by incentivising treatment and providing standard diagnostic modalities to private sector under NTEP.

Competing Interests: Nil

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research